# US 8,784,790 B2 · Method for treating chronic wounds with an extracellular polymeric substance solvating system > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,784,790 B2 - Document ID: US8784790B2 - Status: Granted - Kind: B2 - Application number: 13/124,380 - Filed: 2009-06-11 - Published: 2011-10-06 - Granted: 2014-07-22 - Earliest claimed: 2008-06-12 - Assignees: Medtronic Xomed, Inc. - Applicants: Matthew F. Myntti; Dana A. Oliver; James B. Hissong; Jennifer G. Medina - Inventors: Matthew F. Myntti; Dana A. Oliver; James B. Hissong; Jennifer G. Medina - Web page: https://patentgrep.com/patent/US8784790B2 ## CPC - A61B 17/3205: Excision instruments - A61K 31/09: having two or more such linkages - A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) - A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)} - A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid - A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) - A61K 31/7036: having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins - A61K 33/22: Boron compounds - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61K 47/12: Carboxylic acids; Salts or anhydrides thereof - A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like - A61P 31/04: Antibacterial agents - A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61B 17/3203: Fluid jet cutting instruments - A61B 2017/320004: {abrasive} - A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Chronic wounds may be treated by debriding necrotic and other devitalized tissue from the wound, and applying to the wound an extracellular polymeric substance solvating system comprising a metal ion sequestering agent, surfactant and buffering agent. The solvating system disrupts biofilms which may be present in the wound and aids or enables the resumption of normal healing. ## Claims ### Claim 1 A method for treating chronic wounds, which method comprises: a) debriding at least some necrotic or other devitalized tissue from a chronic skin wound through which subdermal or deeper tissue is exposed, and b) applying to healthy or healable tissue in the wound an extracellular polymeric substance solvating system comprising an aqueous solution of a metal ion sequestering agent, surfactant and buffering agent wherein the solvating system has an osmolarity greater than 900 milliosmoles of solute per liter. ### Claim 2 (depends on 1) A method according to claim 1 wherein the debriding and applying steps are combined by applying the solvating system at a sufficient flow rate or using sufficient pressure to debride at least some devitalized tissue from the wound. ### Claim 3 (depends on 1) A method according to claim 1 comprising applying the solvating system by spraying, lavage, misting, mopping, wicking or dripping and further comprising removing the solvating system from the wound by flushing, rinsing, draining or absorption. ### Claim 4 (depends on 1) A method according to claim 1 wherein the solvating system has an osmolarity of about 1,000 to about 4,000 milliosmoles of solute per liter. ### Claim 5 (depends on 1) A method according to claim 1 wherein the solvating system has an osmolarity of about 1,500 to about 2,600 milliosmoles of solute per liter. ### Claim 6 (depends on 1) A method according to claim 1 wherein the metal ion sequestering agent comprises a mild acid whose acidity is sufficient to sequester one or more metal ions in a bacterial biofilm but which is not so acidic so as to harm healthy or healable tissue in the wound. ### Claim 7 (depends on 1) A method according to claim 1 wherein the metal ion sequestering agent comprises a sequestering agent for sodium, calcium or iron. ### Claim 8 (depends on 1) A method according to claim 1 wherein the metal ion sequestering agent comprises a carboxylic acid, diacid, triacid or mixture thereof. ### Claim 9 (depends on 8) A method according to claim 8 wherein the metal ion sequestering agent comprises formic acid, acetic acid, chloroacetic acid, dichloroacetic acid, oxalic acid, oxamic acid, glycolic acid, lactic acid, pyruvic acid, aspartic acid, fumaric acid, maleic acid, succinic acid, iminodiacetic acid, glutaric acid, 2-ketoglutaric acid, glutamic acid, adipic acid, glucuronic acid, mucic acid, nitrilotriacetic acid, salicylic acid, ketopimelic acid, benzoic acid, mandelic acid, chloromandelic acid, phenylacetic acid, phthalic acid, boric acid or mixture thereof. ### Claim 10 (depends on 8) A method according to claim 8 wherein the metal ion sequestering agent comprises citric acid. ### Claim 11 (depends on 1) A method according to claim 1 wherein the metal ion sequestering agent is present at a concentration of about 0.01 to about 1.5 M. ### Claim 12 (depends on 1) A method according to claim 1 wherein the surfactant comprises a zwitterionic surfactant. ### Claim 13 (depends on 1) A method according to claim 1 wherein the surfactant is about 0.3% to about 30% of the solvating system. ### Claim 14 (depends on 1) A method according to claim 1 wherein the solvating system comprises sufficient buffering agent so that the solvating system has a pH greater than about 4. ### Claim 15 (depends on 1) A method according to claim 1 wherein the solvating system comprises sufficient buffering agent so that the solvating system has a pH greater than about 5 and less than about 8.5. ### Claim 16 (depends on 1) A method according to claim 1 wherein the solvating system further comprises an antimicrobial agent. ### Claim 17 (depends on 16) A method according to claim 16 wherein the antimicrobial agent comprises a topical antibiotic. ### Claim 18 (depends on 16) A method according to claim 16 wherein the antimicrobial agent comprises a peptide. ### Claim 19 (depends on 16) A method according to claim 16 wherein the antimicrobial agent comprises a bacterially selective peptide. ### Claim 20 (depends on 16) A method according to claim 16 wherein the antimicrobial agent comprises gallium acetoacetonate, gallium bromide, gallium chloride, gallium fluoride, gallium iodide, gallium maltolate, gallium nitrate, gallium nitride, gallium percolate, gallium phosphite, gallium sulfate or mixture thereof. ### Claim 21 (depends on 1) A method according to claim 1 comprising treating a foot or leg wound in a diabetic patient. ### Claim 22 (depends on 1) A method according to claim 1 comprising treating the wound to disrupt a bacterial biofilm and discourage its return. ### Claim 23 A method for treating a chronic wound, which method comprises applying to healthy or healable tissue in a chronic skin wound through which subdermal or deeper tissue is exposed an extracellular polymeric substance solvating system comprising an aqueous solution of a metal ion sequestering agent, surfactant and buffering agent and having an osmolarity of about 1,000 to about 4,000 milliosmoles of solute per liter. ### Claim 24 (depends on 1) A method according to claim 1 comprising performing debriding step a) using an extracellular polymeric substance solvating system of step b). ### Claim 25 (depends on 1) A method according to claim 1 wherein the solvating system has an osmolarity greater than 900 milliosmoles of solute per liter. ### Claim 26 (depends on 1) A method according to claim 1 wherein the solvating system has an osmolarity of at least 1,000 milliosmoles of solute per liter.